Fluticasone Propionate And Salmeterol Powder
Product Images NDC 69097-662

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 69097-662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

100-50-carton-label (100 50 Carton Label)

100-50-carton-label (100 50 Carton Label)
Packaging label for Fluticasone Propionate and Salmeterol Inhalation Powder, USP, containing 100 mcg/50 mcg strength. The product is intended for oral inhalation only, supplied as 1 inhalation device with 60 blisters. The label includes instructions for use, dosage form as powder for respiratory inhalation, and the labeler Cipla USA Inc.*
FDA Label Image

250-50-carton-label (250 50 Carton Label)

250-50-carton-label (250 50 Carton Label)
Fluticasone Propionate and Salmeterol Inhalation Powder, USP, 250 mcg / 50 mcg, powder dosage form for respiratory inhalation. The packaging carton includes the Cipla USA Inc. labeler, NDC 69077-661-03, and indicates the product is for prescription use only. Instructions for use with an inhaler device and details for dosing and administration are printed on the carton panels.*
FDA Label Image

500-50-carton-label (500 50 Carton Label)

500-50-carton-label (500 50 Carton Label)
Packaging label for Fluticasone Propionate and Salmeterol Inhalation Powder, USP, 500 mcg / 50 mcg strength. The label indicates it is for oral inhalation only and contains 1 inhalation device with a foil strip of 60 blisters. The product is labeled by Cipla USA Inc. Usage instructions and a barcode are also visible on the label.*
FDA Label Image

Figure-1-invagen (Figure 1 Invagen)

Figure-1-invagen (Figure 1 Invagen)
A line graph showing the percentage change in FEV1 over 12 weeks plus an endpoint for four treatments: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg thrice daily, and placebo. Above the x-axis labeled in weeks, the y-axis measures percent change in FEV1. The graph includes a table of subject numbers (N) at various timepoints for each treatment group.*
FDA Label Image

Figure-2-invagen (Figure 2 Invagen)

Figure-2-invagen (Figure 2 Invagen)
A line graph showing the percent change in FEV1 over a 12-hour period starting from Day 1 baseline. It compares four treatments: Fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The graph tracks changes hourly, illustrating the comparative efficacy of the treatments on respiratory function.*
FDA Label Image

Figure-3-invagen (Figure 3 Invagen)

Figure-3-invagen (Figure 3 Invagen)
A line graph depicting the percentage change in FEV1 relative to Day 1 baseline over a 12-hour period for different treatments. The graph compares Fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo, showing their effects on respiratory function over time.*
FDA Label Image

Figure-4-invagen (Figure 4 Invagen)

Figure-4-invagen (Figure 4 Invagen)
Line graph showing percentage change in FEV1 over 24 weeks for three treatments: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, salmeterol 50 mcg, and placebo. Data points illustrate lung function improvement with fluticasone propionate and salmeterol compared to salmeterol alone and placebo, plotted against time in weeks.*
FDA Label Image

Figure-5-invagen (Figure 5 Invagen)

Figure-5-invagen (Figure 5 Invagen)
Line graph showing percentage change in FEV1 over 24 weeks comparing fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, fluticasone propionate 250 mcg alone, and placebo. The graph tracks lung function improvement with data points at multiple time intervals including day 1, week 4, week 12, week 18, and week 24.*
FDA Label Image

Figure-a-invagen (Figure A Invagen)

Figure-a-invagen (Figure A Invagen)
Diagram of a Fluticasone propionate and Salmeterol inhalation powder device by Cipla USA Inc., showing labeled parts including outer case, mouthpiece, counter, thumb grip, and lever for administration.*
FDA Label Image

Figure-b-invagen (Figure B Invagen)

Figure-b-invagen (Figure B Invagen)
An instructional illustration showing a person holding a circular inhalation device for respiratory powder medication. The image highlights the user pressing the top of the device and an arrow indicating a directional motion, likely demonstrating how to prepare or activate the inhaler for use.*
FDA Label Image

Figure-c-invagen (Figure C Invagen)

Figure-c-invagen (Figure C Invagen)
An instructional illustration showing a person holding and pressing a respiratory inhalation device. The image demonstrates the proper hand positioning and actuation motion with an arrow indicating the direction to press the device for use.*
FDA Label Image

Figure-d-invagen (Figure D Invagen)

Figure-d-invagen (Figure D Invagen)
Illustration showing a person demonstrating the use of a respiratory inhalation device, likely for administering Fluticasone propionate and Salmeterol powder. The person is positioning the inhaler near their mouth, preparing to inhale the medication.*
FDA Label Image

Figure-e-invagen (Figure E Invagen)

Figure-e-invagen (Figure E Invagen)
An illustration showing a person using a respiratory inhalation device, likely demonstrating the proper technique for inhaling a powdered medication.*
FDA Label Image

Figure-f-invagen (Figure F Invagen)

Figure-f-invagen (Figure F Invagen)
An instructional illustration showing a person's hands holding a Fluticasone propionate and Salmeterol inhaler device, with a white arrow pointing to the mouthpiece, indicating the direction for use or a step in the inhalation process.*
FDA Label Image

Figure-g-invagen (Figure G Invagen)

Figure-g-invagen (Figure G Invagen)
An illustration showing a woman performing a respiratory inhalation using a device, likely demonstrating correct inhaler use. A glass of water and a sink faucet are visible nearby, indicating a setting for respiratory medication administration.*
FDA Label Image

Figure-h-invagen (Figure H Invagen)

Figure-h-invagen (Figure H Invagen)
Packaging label for Fluticasone propionate and Salmeterol 100 mcg/50 mcg inhalation powder by Cipla USA Inc., designed for respiratory (inhalation) use. The label is attached to a plastic inhalation device featuring a dosing mechanism and a mouthpiece cover.*
FDA Label Image

Structure-fluticasone-invagen (Structure Fluticasone Invagen)

Structure-fluticasone-invagen (Structure Fluticasone Invagen)
Chemical structure of Fluticasone propionate, showing its molecular arrangement with labeled atoms and bonds, consistent with the active ingredient Fluticasone propionate in the product.*
FDA Label Image

Strudture-salmeterol-invagen (Structure Salmeterol Invagen)

Strudture-salmeterol-invagen (Structure Salmeterol Invagen)
Chemical structure diagram of the active ingredients Fluticasone propionate and Salmeterol. The image displays the molecular layout of these compounds used in the respiratory powder formulation by Cipla USA Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.